Compare Gold Fields Limited (GFI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gold Fields Limited trades at $36.8 (market cap $32.04B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Gold Fields Limited is far larger — about 32.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gold Fields Limited pays a 6.06% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GFI | MRVI | |
|---|---|---|
Market Cap | $32.04B | $977.37M |
Volume | 3,910,984 | 2,742,564 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $9.00 |
52-Week Low | $31.25 | $2.83 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $32.64B | $1.08B |
Dividend Yield | 6.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.34, down 1.14% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 7.24, net income margin of 38.66%, and robust cash flow growth, with 2025 operating cash flow at $3.77 billion. Recent news highlights the company's pursuit of a combination with Northern Star, which was rejected, causing volatility. Earnings have been mixed, with three of the last four quarters missing expectations, but revenue and profitability trends are upward.
The outlook is cautiously optimistic due to solid financials and analyst support, with a consensus price target of $49.06 implying 35% upside. Key risks include execution of growth plans, gold price volatility, and integration challenges from potential M&A. Investor sentiment is divided, with technicals bearish but fundamentals strong, suggesting potential for recovery if operational targets are met.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
